Citations

Showing 10 of 108119 citations.

Management of Chronic Subdural Hematoma in Patients Requiring Therapeutic Anticoagulation
Neth, Bryan J. , Ighodaro, Eseosa T. , Brinjikji, Waleed , Cloft, Harry J. , Cloft, Harry, Neth, Byran J. , Scharf, Eugene

Mayo Clinic

The Neurologist | December 2, 2021 | Volume: 27 | Issue: 4 | Pages: 211-213

10.1097/nrl.0000000000000380 | PMID 34855670 Get It

Introduction: A common risk factor of chronic, nontraumatic subdural hematoma (SDH) is anticoagulation therapy. Anticoagulation is generally held in patients who develop SDH, but this can lead to thromboembolic events. While prior studies have reported the clinical outcomes of patients with anticoagulation-related SDH, there remains little evidence regarding ongoing anticoagulation treatment. Case Report: We report the management of 2 patients who developed anticoagulation-related SDH and underwent middle meningeal artery (MMA) embolization and successful reinitiation of anticoagulation therapy. In both patients, we conservatively managed anticoagulation with heparin and/or enoxaparin as a bridge to warfarin after MMA embolization. Follow-up computed tomography head revealed interval decrease of SDH and stable neurological status. Conclusions: These cases provide anecdotal evidence of a challenging clinical scenario where there is a necessary indication for therapeutic anticoagulation (ie, venous sinus thrombosis or atrial appendage thrombus) and comorbid SDH. Endovascular MMA embolization may be an effective adjunct therapy for clinical scenarios in patients with SDH and an urgent indication for anticoagulation. Longer follow-up, prospective series, and future randomized clinical trials are needed to objectively assess outcomes in this clinically challenging patient population.
Reversible Cerebral Vasoconstriction Syndrome in the Setting of COVID-19 and Pleomorphic Sarcoma
Harahsheh, Ehab , Gritsch, David , Mbonde, Amir A. , Apolinario, Michael , Hoxworth, Joseph M. , Demaerschalk, Bart M.

Mayo Clinic

The Neurologist | December 2, 2021 | Volume: 27 | Issue: 3 | Pages: 135-138

10.1097/nrl.0000000000000387 | PMID 34855668 Get It

Introduction: Reversible cerebral vasonstriction syndrome (RCVS) is an increasingly recognized clinical and radiologic syndrome. However, it has been rarely reported in the setting of the novel coronavirus disease-2019 (COVID-19) infection or sarcomatous tumors. RCVS might be the initial manifestations of COVID-19 infection or noncatecholamine producing masses including sarcoma. Case Report: A 44-year-old male who developed COVID-19–related symptoms followed by rapid onset of severe headaches in the setting of persistently elevated blood pressure (BP). Brain imaging showed multifocal arterial narrowing in the anterior and posterior circulation consistent with RCVS. Serial imaging demonstrated resolution of the arterial narrowing after BP control was achieved with improvement in the patient’s headaches. Further investigation for secondary causes of the patient’s elevated BP revealed a right renal mass, and the patient underwent right nephrectomy, and the biopsy results confirmed the diagnosis of pleomorphic sarcoma. Conclusion: Our case suggests a possible association between severe acute respiratory syndrome coronavirus 2 with development of RCVS, but further studies are needed to validate this observation, establish a causal relationship and define a pathophysiological mechanism. Considering tumors other than catecholamine-producing masses as a potential risk factor for developing RCVS might lead to earlier detection and treatment of any underlying malignancy in patients whom the main and sole presentation could be RCVS.
Temporal Trends in Glioblastoma Survival
Neth, Bryan J. , Carabenciov, Ivan D. , Ruff, Michael W. , Neth, Byran J. , Johnson, Derek R.

Mayo Clinic

The Neurologist | December 2, 2021 | Volume: 27 | Issue: 3 | Pages: 119-124

10.1097/nrl.0000000000000393 | PMID 34855660 Get It

Background: Survival of patients with glioblastoma (GBM) increased in the 2000s, most prominently after the addition of temozolomide to the standard-of-care treatment protocol. The reason for subsequent improvements in survival in the late 2000s and early 2010s was less clear, with explanations including the introduction of bevacizumab, better surgical methods, and advances in supportive care. It is uncertain whether the trend of improving population-level survival has continued. Materials and Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) Program was analyzed comparing survival of adult GBM patients diagnosed in consecutive 3-year periods from 2000 to 2017. Kaplan-Meier survival analysis and Cox proportional hazards models were used. Results: A total of 38,352 patients diagnosed with GBM between 2000 and 2017 met inclusion criteria. Median survival and percent survival to 12 and 24 months all progressively increased between 2000 and 2011. There were no significant differences in survival comparing 2009-2011 with 2012-2014 or 2015-2017. During the 2015-2017 period, median survival was 11 months, with 12 and 24-month survival proportions of 45.7% (95% confidence interval, 44.5-47.0) and 19.0% (95% confidence interval, 18.6-21.2), respectively. Conclusions: After a period of progressive improvement in GBM survival between 2000 and 2011, survival plateaued. Subsequent advances since 2011 have not yet been translated to improved survival on the population-level as of 2017.
Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination
Terpos, Evangelos , Terpos, Evangelos , Rajkumar, S. Vincent , Leung, Nelson

Mayo Clinic

JAMA Oncology | December 2, 2021 | Volume: 8 | Issue: 2 | Pages: 201

10.1001/jamaoncol.2021.5942 | PMID 34854888 Get It

An ACVR1R375P pathogenic variant in two families with mild fibrodysplasia ossificans progressiva
Kaplan, Frederick S. , Groppe, Jay C. , Xu, Meiqi , Towler, O. Will , Grunvald, Eduardo , Kallish, Staci , Mukaddam, Mona Al , Pignolo, Robert J. , Shore, Eileen M. , Shore, Eileen M , Kaplan, Frederick S , Grunvald, Eduardo , Kalunian, Kenneth

Mayo Clinic

American Journal of Medical Genetics Part A | December 2, 2021 | Volume: 188 | Issue: 3 | Pages: 806-817

10.1002/ajmg.a.62585 | PMID 34854557 Get It

AbstractGenetic variants are vital in informing clinical phenotypes, aiding physical diagnosis, guiding genetic counseling, understanding the molecular basis of disease, and potentially stimulating drug development. Here we describe two families with an ultrarare ACVR1 gain‐of‐function pathogenic variant (codon 375, Arginine > Proline; ACVR1R375P) responsible for a mild nonclassic fibrodysplasia ossificans progressiva (FOP) phenotype. Both families include people with the ultrarare ACVR1R375P variant who exhibit features of FOP while other individuals currently do not express any clinical signs of FOP. Thus, the mild ACVR1R375P variant greatly expands the scope and understanding of this rare disorder.
Digital stress management in cancer: Testing StressProffen in a 12‐month randomized controlled trial
Børøsund, Elin , Ehlers, Shawna L. , Clark, Matthew M. , Andrykowski, Michael A. , Småstuen, Milada Cvancarova, Nes, Lise Solberg , Hagen, Milada , Cvancarova, Milada , Solberg Nes, Lise , Børøsund, Elin

Mayo Clinic

Cancer | December 2, 2021 | Volume: 128 | Issue: 7 | Pages: 1503-1512

10.1002/cncr.34046 | PMID 34855212 Get It

BACKGROUNDCognitive‐behavioral stress management interventions are associated with improved psychological well‐being for cancer survivors. The availability of, access to, and outreach of these in‐person interventions are limited, however. The current study, therefore, evaluated the efficacy of StressProffen, a digital application (app)–based stress management intervention for cancer survivors, in a 12‐month randomized controlled trial.METHODSCancer survivors 1 year or less after their treatment (N = 172) were randomized to the StressProffen intervention (n = 84) or a usual‐care control group (n = 88). The intervention was delivered in a simple blended care model: 1) 1 in‐person introduction session, 2) 10 app‐based cognitive‐behavioral stress management modules, and 3) 2 follow‐up phone calls. Stress (Perceived Stress Scale), anxiety and depression (Hospital Anxiety and Depression Scale), self‐regulatory fatigue (Self‐Regulatory Fatigue 18), and health‐related quality of life (HRQOL; RAND‐36) were examined at the baseline and at 6 and 12 months. Generalized linear models for repeated measures were fitted to compare effects over time.RESULTSParticipants were mainly female (82%), had a mean age of 52 years (standard deviation, 11.3 years; range, 20‐78 years), and had a variety of cancer types (mostly breast cancer [48%]). Over the 12‐month study time, the intervention group reported significantly decreased stress (P < .001), depression (P = .003), and self‐regulatory fatigue (P = .002) as well as improved HRQOL (for 6 of 8 domains, P ≤ .015) in comparison with controls. The largest favored effects for the intervention group were observed at 6 months: stress (estimated mean difference [MD], –5.1; P < .001), anxiety (MD, –1.4; P = .015), depression (MD, –2.1; P < .001), self‐regulatory fatigue (MD, –4.9; P < .001), and HRQOL (7 of 8 domains; P ≤ .037).CONCLUSIONSDigital stress management interventions such as StressProffen have the potential to extend the outreach of psychological interventions and provide easily available and effective psychosocial support for cancer survivors.
Editor's evaluation: A 3D adult zebrafish brain atlas (AZBA) for the digital age
Ekker, Stephen C.

Mayo Clinic

No container title available | December 2, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.69988.sa0 Get It

Evaluating educational interventions to increase breast density awareness among Latinas: A randomized trial in a Federally Qualified Health Center
Ridgeway, Jennifer L. , Jenkins, Sarah M. , Borah, Bijan J. , Patel, Bhavika , Ghosh, Karthik, Rhodes, Deborah J. , Ramos, Edna P., Jewett, Matt, Gonzalez, Crystal, Hernandez, Valentina, Sosa, Miranda, Breitkopf, Carmen Radecki , Vachon, Celine M. , Patel, Bhavika K , Norman, Aaron, Vachon, Celine M. , Ridgeway, Jennifer L , Borah, Bijan J , Suman, Vera J. , Norman, Aaron D. , Singh, Davinder

Mayo Clinic

Cancer | December 2, 2021 | Volume: 128 | Issue: 5 | Pages: 1038-1047

10.1002/cncr.34017 | PMID 34855208 Get It

BackgroundThe objective of this randomized trial was to evaluate the short‐term effect of bilingual written and interpersonal education regarding mammographic breast density (MBD).MethodsLatinas aged 40 to 74 years who were presenting for screening mammography were recruited and randomized 1:1:1 to receive a letter with their mammogram and MBD results (usual care [UC]), a letter plus a brochure (enhanced care [ENH]), or a letter plus a brochure and telephonic promotora education (interpersonal care [INT]). Surveys were administered at enrollment (T0) and 2 weeks to 6 months after intervention delivery (T1). Differences were assessed with χ2, Kruskal‐Wallis, and McNemar tests and pairwise comparisons as appropriate. INT metrics and audio recordings were analyzed with descriptive statistics and qualitative content analysis.ResultsBetween October 2016 and October 2019, 943 of 1108 Latina participants (85%) completed both surveys. At T1, INT participants were more likely (P < .001) to report seeing their MBD results in the letter (70.2%) than UC (53.1%) or ENH participants (55.1%). The percentage of INT women who reported speaking with a provider about MBD (29.0%) was significantly greater (P < .001) than the percentage of UC (14.7%) or ENH participants (15.6%). All groups saw significant (P < .001) but nondifferential improvements in their knowledge of MBD as a masking and risk factor. In the INT group, the promotora delivered education to 77.1% of the 446 participants randomized to INT and answered questions at 28.3% of the encounters for an average of $4.70 per participant.ConclusionsAmong Latinas in a low‐resource setting, MBD knowledge may increase with written or interpersonal education, but with modest investment, interpersonal education may better improve MBD awareness and prompt patient‐provider discussions.
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment
Sandborn, William J. , Lawendy, Nervin, Su, Chinyu , Loftus, Edward V. , Hart, Ailsa , Dotan, Iris , Damião, Adérson Omar Mourão Cintra , Judd, Donna T., Modesto, Irene , Wang, Wenjin , Danese, Silvio , Loftus, Edward V , Danese, Silvio , Guo, Xiang , Panés, Julián

Mayo Clinic

Alimentary Pharmacology & Therapeutics | December 2, 2021 | Volume: 55 | Issue: 4 | Pages: 464-478

10.1111/apt.16712 | PMID 34854095 Get It

SummaryBackgroundTofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present final data from OCTAVE Open, an open‐label, long‐term extension study.AimsThe primary objective of OCTAVE Open was to assess the safety and tolerability of long‐term tofacitinib in patients with ulcerative colitis; evaluating efficacy was a secondary objective.MethodsEligible patients included OCTAVE Induction 1&2 non‐responders and OCTAVE Sustain completers/treatment failures. Patients in remission at OCTAVE Open baseline received tofacitinib 5 mg b.d.; all others received 10 mg b.d. Incidence rates (unique patients with events/100 patient‐years) for adverse events of special interest were calculated; ≤7.0 years of observation. Efficacy endpoints derived from Mayo score were reported ≤36 months (last scheduled endoscopy visit).ResultsIn OCTAVE Open, 769 of 944 patients (81.5%) initially received tofacitinib 10 mg b.d. Among all patients (2440.8 patient‐years of exposure), incidence rates (IRs; 95% confidence intervals) for deaths and adverse events of special interest were: deaths, 0.25 (0.09‐0.54); serious infections, 1.61 (1.14‐2.20); herpes zoster (non‐serious and serious), 3.16 (2.47‐3.97); opportunistic infections, 0.87 (0.54‐1.33); major adverse cardiovascular events, 0.16 (0.04‐0.42); malignancies (excluding non‐melanoma skin cancer), 1.03 (0.67‐1.52); non‐melanoma skin cancer, 0.75 (0.45‐1.19); deep vein thrombosis, 0.04 (0.00‐0.23); pulmonary embolism, 0.21 (0.07‐0.48). At Month 36, 66.9% and 40.3% showed clinical response, 64.6% and 37.1% had endoscopic improvement, and 58.9% and 33.7% maintained or achieved remission, with tofacitinib 5 and 10 mg b.d. respectively.ConclusionTofacitinib demonstrated consistent safety up to 7.0 years. Data collected up to Month 36 support long‐term efficacy beyond the 52‐week maintenance study.